✦ LIBER ✦

A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia

✍ Scribed by Mannis, Gabriel N.; Damon, Lloyd E.; Ai, Weiyun; Andreadis, Charalambos; Gaensler, Karin ML.; Kaplan, Lawrence D.; Logan, Aaron C.; Mahindra, Anuj; Olin, Rebecca L.; Sayre, Peter; Smith, Catherine C.; Venstrom, Jeffrey M.; Wolf, Jeffrey L.; Martin, Thomas G.

Book ID: 122240157
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 74 KB
Volume: 20
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2013.12.167

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-dependent effect of etoposide in co

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

✍ Kröger, N; Zabelina, T; Sonnenberg, S; Krüger, W; Renges, H; Stute, N; Finkenste 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 74 KB

18: Autologous peripheral blood stem cel

18: Autologous peripheral blood stem cell transplant using busulfan, etoposide, high dose Ara-C, and G-CSF priming as conditioning regimen in patients with acute myeloid leukemia in first complete remission

✍ F. Moscardó; J. Dı́az Mediavilla; J. de la Rubia; P. Fernández; C. Rayón; G. Cañ 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Phase 2 study of targeted intravenous bu

Phase 2 study of targeted intravenous busulfan (IV BU) combined with fractionated total body irradiation (FTBI) and etoposide (VP-16) as preparative regimen for allogeneic peripheral blood stem cell transplant (PBSCT) for patients with poor risk leukemia

✍ A.S. Stein; M.R. O’Donnell; A. Dagis; A. Krishnan; A. Nademanee; R. Nakamura; P. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

A Phase 1 Dose-Escalation Study To Evalu

A Phase 1 Dose-Escalation Study To Evaluate The Safety And Pharmacokinetics Of Palifermin In Pediatric Subjects With Acute Leukemias Undergoing Myeloablative Therapy And Allogeneic Hematopoietic Stem Cell Transplant

✍ J. Morris; S. Neudorf; T. Moore; A. Shah; M. Graham; V. Aquino; R. Duerst; M. Ne 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Multicenter randomized phase II trial of

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia

✍ Archimbaud, E; Jehn, U; Thomas, X; De Cataldo, F; Fillet, G; Belhabri, A; Peaud, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB

Bortezomib Followed by a Phase I Study o

Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia

✍ T. Nishihori; T.J. Alekshun; D.M. Sullivan; M.A. Kharfan-Dabaja; J. Raychaudhuri 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 86 KB